Ionis Pharmaceuticals, Inc.: updates and filings

IONSNASDAQHealthcare · Pharmaceutical Preparations

Price

$29.06

November 13, 2026Market cap $4.8B

DCF calculator

What Ploutos Investor adds for Ionis Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans

The full history: 17 fiscal years, from 2009
The estimated fair value, with its range and its certainty
The full analysis, 18 a month
More questions to the chat on its filings
Excel with every year
An email when it reports, changes its dividend or an officer buys

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 76 daysAround Jan 29, 2027 · for Q4 2026

last Nov 9, 2026next Jan 29, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

November 2026

October 2026

September 2026

July 2026

June 2026

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 26, 2026 latest annualNov 9, 2026 latest quarterly

Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026
Form10-Q
Nov 9, 2026Results of operations
Form8-K
Oct 23, 2026Regulation FD disclosure, other material events
Form8-K
Oct 21, 2026Regulation FD disclosure, other material events
Form8-K
Sep 23, 2026Regulation FD disclosure, other material events
Form8-K
Sep 4, 2026Regulation FD disclosure, other material events
Form8-K
Sep 4, 2026Regulation FD disclosure, other material events
Form8-K
Jul 31, 2026Shares registered for employees
FormS-8
Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026
Form10-Q
Jul 29, 2026Results of operations
Form8-K
Jul 10, 2026Regulation FD disclosure
Form8-K
Jul 9, 2026Regulation FD disclosure, other material events
Form8-K
Jun 24, 2026Regulation FD disclosure, other material events
Form8-K
Jun 12, 2026Other material events
Form8-K
Jun 8, 2026Officer or director change, shareholder vote, Regulation FD disclosure
Form8-K
May 28, 2026Regulation FD disclosure, other material events
Form8-K
May 15, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
May 14, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Apr 30, 2026Over-5% holder statement (passive)
FormSCHEDULE 13G
Apr 29, 2026Quarterly reportfor the period to Mar 31, 2026
Form10-Q
Apr 29, 2026Results of operations
Form8-K
Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025
FormARS
Apr 23, 2026Additional annual meeting material
FormDEFA14A
Apr 23, 2026Annual meeting proxy statement
FormDEF 14A
Apr 21, 2026Regulation FD disclosure, other material events
Form8-K

Filed	Form	What it is	Filing
Nov 9, 2026	10-Q	Quarterly reportfor the period to Sep 30, 2026	Document
Nov 9, 2026	8-K	Results of operations	Document
Oct 23, 2026	8-K	Regulation FD disclosure, other material events	Document
Oct 21, 2026	8-K	Regulation FD disclosure, other material events	Document
Sep 23, 2026	8-K	Regulation FD disclosure, other material events	Document
Sep 4, 2026	8-K	Regulation FD disclosure, other material events	Document
Sep 4, 2026	8-K	Regulation FD disclosure, other material events	Document
Jul 31, 2026	S-8	Shares registered for employees	Document
Jul 29, 2026	10-Q	Quarterly reportfor the period to Jun 30, 2026	Document
Jul 29, 2026	8-K	Results of operations	Document
Jul 10, 2026	8-K	Regulation FD disclosure	Document
Jul 9, 2026	8-K	Regulation FD disclosure, other material events	Document
Jun 24, 2026	8-K	Regulation FD disclosure, other material events	Document
Jun 12, 2026	8-K	Other material events	Document
Jun 8, 2026	8-K	Officer or director change, shareholder vote, Regulation FD disclosure	Document
May 28, 2026	8-K	Regulation FD disclosure, other material events	Document
May 15, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
May 14, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Apr 30, 2026	SCHEDULE 13G	Over-5% holder statement (passive)	Document
Apr 29, 2026	10-Q	Quarterly reportfor the period to Mar 31, 2026	Document
Apr 29, 2026	8-K	Results of operations	Document
Apr 23, 2026	ARS	Annual report to shareholdersfor the period to Dec 31, 2025	Document
Apr 23, 2026	DEFA14A	Additional annual meeting material	Document
Apr 23, 2026	DEF 14A	Annual meeting proxy statement	Document
Apr 21, 2026	8-K	Regulation FD disclosure, other material events	Document

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Jun 12, 1996: every report, 8-K, meeting and letter. Of its other filings (954 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 47.

And 1,723 filings on insiders' shares1,493 Form 4, 187 Form 144 and 37 Form 3 since Sep 30, 2002. Their trades are on the Ownership tab.

The full analysis

What do Ionis Pharmaceuticals's filings show?

The filings are where every one of Ionis Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

A fair value range built from the filings
Earnings quality, debt and red flags
Insider and institutional moves
The case for and the case against

All filings on EDGAR

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.